<code id='B4F0A1D51B'></code><style id='B4F0A1D51B'></style>
    • <acronym id='B4F0A1D51B'></acronym>
      <center id='B4F0A1D51B'><center id='B4F0A1D51B'><tfoot id='B4F0A1D51B'></tfoot></center><abbr id='B4F0A1D51B'><dir id='B4F0A1D51B'><tfoot id='B4F0A1D51B'></tfoot><noframes id='B4F0A1D51B'>

    • <optgroup id='B4F0A1D51B'><strike id='B4F0A1D51B'><sup id='B4F0A1D51B'></sup></strike><code id='B4F0A1D51B'></code></optgroup>
        1. <b id='B4F0A1D51B'><label id='B4F0A1D51B'><select id='B4F0A1D51B'><dt id='B4F0A1D51B'><span id='B4F0A1D51B'></span></dt></select></label></b><u id='B4F0A1D51B'></u>
          <i id='B4F0A1D51B'><strike id='B4F0A1D51B'><tt id='B4F0A1D51B'><pre id='B4F0A1D51B'></pre></tt></strike></i>

          focus

          focus

          author:fashion    Page View:737
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Novartis is flashing warning signs about its newly acquired myelofibrosis drug
          Novartis is flashing warning signs about its newly acquired myelofibrosis drug

          MollyFerguson/STATCHICAGO—SomethingisoffaboutthewayNovartisistalkingaboutpelabresib,itsnewlyacquired

          read more
          George Santos makes 1st court appearance after pleading not guilty to 13 counts
          George Santos makes 1st court appearance after pleading not guilty to 13 counts

          1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

          read more

          Senators tussle over abortion against the backdrop of a presidential campaign

          Sen.BillCassidy(R-La.),amemberofthechamber'shealthcommittee,saidduringthehearing:“It'spartisanpoliti